Clinical effect of Entecavir combined with Heluoshugan Capsules treating hepatitis B cirrhosis of compensated stage
ZHANG Li-yi1 2 DING Guo-feng3▲
1.Binzhou Medicical University in Shandong Province,Yantai264000,China;
2.Department of Gastroenterology,Central Hospital of Jiaozhou in Qingdao City of Shandong Province,Qingdao266300,China;
3.Department of Infectious Disease, Affiliated Hospital of Binzhou Medicical University in Shandong Province,Binzhou256600,China
Abstract：Objective To observe the clinical effect of Entecavir combined with Heluoshugan Capsules treating hepatitis B cirrhosis of compensated stage.Methods 82 patients with hepatitis B cirrhosis of compensated stage diagnosed and treated by department of gastroenterology in Central Hospital of Jiaozhou of Qingdao City from June 2011 to May 2012 were selected and they were randomly divided into treatment group of 41 cases and control group of 41 cases.Control group was treated with oral Entecavir Disket 0.5 mg,once a day,while the treatment group was treated with oral Heluoshugan Capsules for 5 capsules,three times a day,and taking Heluoshugan Capsules for 2 months and stopping 1 month and then continued to take according to the law,and both groups received 48 months treatment.Treatment effect between two groups was compared.Results Albumin(Alb)level in two groups were significantly different(t=6.351,P=0.017),the treatment group was better than the control group;the level of serum hyaluronie acid(HA),Laminin(LN),procollagen typeⅢ(PC-Ⅲ)and collagen typeⅣ-C(Ⅳ-C)were decreased significantly in treatment group than in control group, and the above-mentioned indexes were better than those in control group(P＜0.01).The negative conversion rate of treatment group(41.4%)was significantly higher than that of control group(14.6%)(P＜0.01).There was a statistical difference of the portal vein diameter between two groups(P＜0.01),but there was no significant difference in negative conversion rate of HBV-DNA(P＞0.05).Conclusion Entecavir combined with Heluoshugan Capsules treating hepatitis B cirrhosis of compensated stage can improve liver function,suppress viral replication persistently,and can delay or even reverse the progression of liver fibrosis,and it has clinical application value.
Tseng PL，Lu SN，Tung HD，et al.Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis[J].J Viral Hepat，2005，12（4）：386-392.
Abu-Amara M，Feld JJ.Does antiviral therapy for chronic hepatitis B reduce the risk of hepatcel lular carcinoma?[J]. Semin Liver Dis，2013，33（2）：157-166.
Kim JK，Ma DW，Lee KS，et al.Assessment of hepatic fibrosisregression by transient elastography in patients with chronic hepatitis B treated with oral antiviral agents[J].J Korean Med Sci，2014，29（4）：570-575.
Cheng Y，Ping J，Liu C，et al．Study on effects of extracts from Salvia Miltiorrhiza and Curcuma Longa in inhibiting phosphorylated extracellular signal regulated kinase expression in rate hepatic stellate cells[J]．Chin J Integr Med，2006，12（3）：207-211．
京公网安备 11010502046607号